Table 1

Characteristics of 53 patients with therapy related myeloid neoplasms (t-MNs) studied

CharacteristicNumber (%)
Age, years
 Median62
 Mean56
 Range2–85
Female35 (66)
Male18 (34)
Primary neoplasms63 (100)
 Solid tumours37 (59)
  Breast cancer18 (29)
  Sarcoma6 (10)
  Colon cancer2 (3)
  Other11 (17)
 Haematological malignancies26 (41)
  Non-Hodgkin's lymphoma16 (25)
  Acute myeloid leukaemia4 (6)
  Acute lymphoblastic leukaemia2 (3)
  Hodgkin's disease2 (3)
  Plasma cell myeloma2 (3)
Primary cytotoxic treatments
 Alkylating agents29 (55)
 Topoisomerase II inhibitors12 (23)
 Antimetabolites20 (38)
 Ionising radiation34 (64)
 ASCT5 (9)
 Others35 (66)
t-MNs at presentation
 t-MDS23 (43)
 t-AML28 (53)
 t-MDS/MPN2 (4)
Latency period, months
 Median53
 Range6–420
Progression t-MDS → t-AML14 (61)
 Median time, months3
 Range, months1–31
  • ASCT, autologous haematopoietic stem cell transplantation; t-AML, therapy related acute myeloid leukaemia; t-MDS, therapy related myelodysplastic syndrome; MPN, myeloproliferative neoplasm.